Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderate-to-severe plaque psoriasis. Sold as Ilumya. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Tildrakizumab-Asmn (sold as Ilumya), first approved Mar 20, 2018, with 5 new uses approved and 0 published complete response letters.
First approved: Mar 20, 2018
Applications: 1
New uses approved: 5
Complete response letters: 0
Medicare spending, 2025: $495M
First approved in the EU: Sep 17, 2018
First approved in Japan: Jun 29, 2020
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 27 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Ilumya, new ingredientA drug with a new active ingredient indicated for the treatment of plaque psoriasis in patients who have not responded sufficiently to conventional therapies. · Sun Pharma Japan Ltd. · Jun 29, 2020
Clinical Trials
16 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
